Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells

Cancer Research

Volumn 60, Issue 16, 2000, Pages 4493-4498

  Rawson, Pisana ^a   Hermans, Ian F ^a   Huck, Stephanie P ^a   Roberts, Joanna M ^a   Pircher, Hanspeter ^b   Ronchese, Franca ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR CELL LINE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CARCINOMA, LEWIS LUNG; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; GLYCOPROTEINS; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED; VIRAL PROTEINS;

EID: 0034662628     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines
2. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
3. New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitopebased peptide vaccines
4. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8(+) cytolytic T lymphocytes
5. Superdominance among immunodominant H-2K(b)-restricted epitopes and reversal by dendritic cell-mediated antigen delivery
6. Human tumor antigens recognized by T cells
7. Optimal T cell activation by melanoma cells depends on a minimal level of Antigen transcription
8. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines
9. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
10. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms: Functional significance and clinical relevance
11. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
12. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo
13. Tumor-peptidepulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge
14. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen
15. Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors
16. Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution
17. The JAM test: A simple assay for DNA fragmentation and cell death
18. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases
19. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response
20. Peptides naturally presented by MHC class I molecules
21. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies?